在nash找到适用于iOS和Android移动设备的AGA\的NASH临床护理路径应用程序。gast.org.扫描此QR码直接带到网站。非酒精性脂肪性肝病(NAFLD)变得越来越普遍,目前影响了大约37%的美国成年人。NAFLD最常见于初级保健或内分泌诊所,临床医生必须确定哪些患者可能受益于二级保健,以解决肝脏表现,共病代谢性状,和心血管疾病的风险。因为NAFLD基本上是无症状的,因为最佳治疗时机取决于纤维化风险的准确分期,初级保健层面的筛查至关重要,与一致的,及时,以证据为基础,可广泛使用,和可测试的管理流程。为了实现这些目标,美国胃肠病学协会组建了一个多学科专家小组,以制定临床护理路径,为筛查提供明确的指导,诊断,和NAFLD的治疗。本文描述了他们开发的NAFLD临床护理路径,并提供了支持建议步骤的基本原理,以帮助临床医生诊断和管理具有临床显着纤维化(F2-F4期)的NAFLD。本路径旨在适用于为NAFLD患者提供护理的任何环境。包括初级保健,内分泌,肥胖医学,和胃肠病学实践。
Find AGA\'s NASH Clinical Care Pathway App for iOS and Android mobile devices at nash.gastro.org. Scan this QR code to be taken directly to the website.Nonalcoholic fatty liver disease (NAFLD) is becoming increasingly common, currently affecting approximately 37% of US adults. NAFLD is most often managed in primary care or endocrine clinics, where clinicians must determine which patients might benefit from secondary care to address hepatic manifestations, comorbid metabolic traits, and cardiovascular risks of the disease. Because NAFLD is largely asymptomatic, and because optimal timing of treatment depends on accurate staging of fibrosis risk, screening at the primary care level is critical, together with consistent, timely, evidence-based, widely accessible, and testable management processes. To achieve these goals, the American Gastroenterological Association assembled a multidisciplinary panel of experts to develop a Clinical Care Pathway providing explicit guidance on the screening, diagnosis, and treatment of NAFLD. This article describes the NAFLD Clinical Care Pathway they developed and provides a rationale supporting proposed steps to assist clinicians in diagnosing and managing NAFLD with clinically significant fibrosis (stage F2-F4) based on the best available evidence. This Pathway is intended to be applicable in any setting where care for patients with NAFLD is provided, including primary care, endocrine, obesity medicine, and gastroenterology practices.